Breaking News
Black Friday SALE: Up to 54% off InvestingPro! Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat

By Zacks Investment ResearchStock MarketsMay 09, 2019 02:00AM ET
www.investing.com/analysis/intercept-icpt-q1-earnings-miss-estimates-revenues-beat-200419724
Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat
By Zacks Investment Research   |  May 09, 2019 02:00AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) gained 3.02% after the company posted mixed results for the first quarter. The company reported a wider-than-expected loss but beat on sales expectations.

The company incurred a loss of $3.03 per share in the first quarter, wider than the Zacks Consensus Estimate of a loss of $2.57 but narrower than the year-ago loss of $3.22.

Quarterly revenues were $52.2 million, up from $35.9 million in the year-ago quarter. Revenues also marginally surpassed the Zacks Consensus Estimate of $52 million.

Quarter in Detail

Ocaliva recorded $51.8 million of sales, down from $52.9 million recorded in the fourth quarter of 2018 but up from $35.2 million in the year-earlier quarter. Net sales in the United States came in at $38 million, while ex-U.S. Ocaliva net sales summed $13.8 million.

Ocaliva in combination with ursodeoxycholic (UDCA) was approved in the United States in 2016 for the treatment of primary biliary cholangitis (“PBC”) in adults with an inadequate response to UDCA or as monotherapy in adults, who are unable to endure UDCA. The drug was also granted a conditional approval by the European Commission. In February 2018, the drug’s label was updated in the United States to include a boxed warning and a dosing table that reinforced the existing dosing schedule in PBC patients with Child-Pugh Class B or C or decompensated cirrhosis.
Research and development expenses increased 19.9% year over year to $58.4 million, primarily due to more clinical development programs of Ocaliva for NASH. However, selling, general and administrative expenses increased 23.5% to $77.2 million.

2019 Outlook

For 2019, Ocaliva’s net sales are expected between $235 million and $245 million. Intercept continues to expect operating expenses of $470-$500 million for the year.

Pipeline Update

Obeticholic acid (OCA) is also being evaluated for other indications, including non-alcoholic steatohepatitis (“NASH”) and primary sclerosing cholangitis (“PSC”).

Earlier in 2019, Intercept announced positive top-line results from the pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH. The company stated that the primary endpoint of the study — fibrosis improvement without worsening of NASH at 18 months — was achieved with the 25 mg daily dose of OCA.

Also, a numerically greater proportion of patients in both OCA treatment arms (receiving doses of 10 mg and 25 mg) met the primary endpoint of NASH resolution with no deterioration of liver fibrosis as compared to placebo. However, this did not reach statistical significance. Nevertheless, the study was required to attain one of the two primary goals per the FDA, which it did.

In April 2019, additional supportive REGENERATE data were presented during the Opening Ceremony of the International Liver Congress™ 2019, the 54th Annual Meeting of the European Association for the Study of the Liver (“EASL”). The data showed that OCA demonstrated robust efficacy across a range of additional histologic and biochemical parameters.

Intercept plans to file for an approval of OCA as a NASH treatment both in the United States and Europe in the third and fourth quarters, respectively.

The REVERSE study is designed to evaluate the efficacy and safety of Ocaliva in NASH patients suffering from compensated cirrhosis. The study is currently enrolling patients, which is expected to be complete by the end of the year.

Our Take

Intercept’s first-quarter results were mixed, as earnings lagged expectations but sales beat the same. Management’s efforts to increase awareness about the label update of Ocaliva in 2018 and expand sales force across the United States, thereafter, are reaping results. Solid growth in new patient enrollment is likely to drive sales in 2019.

Moreover, the favorable outcomes from the REGENERATE assessment are a big boost to Intercept. This news significantly buoyed investors’ sentiments, given the market potential of NASH and the fact that biotech bigwig Gilead Sciences, Inc. (NASDAQ:GILD) announced the failure of a late-stage study on selonsertib, involving patients afflicted with compensated cirrhosis (F4) due to NASH. This, in turn, puts Intercept ahead in the race to get a drug approved for NASH.

Pharma giant Merck (NYSE:MRK) , in January 2019, exercised its option to license NGM313, an investigational monoclonal antibody agonist of the β-Klotho/FGFR1c receptor complex that is currently being evaluated for the treatment of NASH and type II diabetes.

Shares of the company have rallied 19.1% in the past year compared with the industry’’s loss of 12.9%.

France-based Genfit’s (NASDAQ:GNFT) lead candidate elafibranor, which is in late-stage studies for NASH, also holds promise.

Zacks Rank

Intercept currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.v

This Could Be the Fastest Way to Grow Wealth in 2019

Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.

These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.

Click here to see these breakthrough stocks now >>



Merck & Co., Inc. (MRK): Free Stock Analysis Report

Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report

Gilead Sciences, Inc. (GILD): Free Stock Analysis Report

Genfit SA (GNFT): Get Free Report

Original post

Zacks Investment Research
Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat
 

Related Articles

Trading Point
Can Anything Stop The Stock Market? By Trading Point  - Nov 26, 2021

Stock markets have gone on an absolute rampage this year. The problem is that the factors that initially fueled this rally - heavy government spending and endless central bank...

Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email